-
1
-
-
84866415102
-
A genome-wide association study identifies novel loci for paclitaxelinduced sensory peripheral neuropathy in CALGB 40101
-
Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL (2012) A genome-wide association study identifies novel loci for paclitaxelinduced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 18(18): 5099-5109.
-
(2012)
Clin Cancer Res
, vol.18
, Issue.18
, pp. 5099-5109
-
-
Baldwin, R.M.1
Owzar, K.2
Zembutsu, H.3
Chhibber, A.4
Kubo, M.5
Jiang, C.6
Watson, D.7
Eclov, R.J.8
Mefford, J.9
McLeod, H.L.10
Friedman, P.N.11
Hudis, C.A.12
Winer, E.P.13
Jorgenson, E.M.14
Witte, J.S.15
Shulman, L.N.16
Nakamura, Y.17
Ratain, M.J.18
Kroetz, D.L.19
-
2
-
-
84864599004
-
Guidelines for genome-wide association studies
-
Barsh GS, Copenhaver GP, Gibson G, Williams SM (2012) Guidelines for genome-wide association studies. PLoS Genet 8(7): e1002812.
-
(2012)
PLoS Genet
, vol.8
, Issue.7
, pp. e1002812
-
-
Barsh, G.S.1
Copenhaver, G.P.2
Gibson, G.3
Williams, S.M.4
-
3
-
-
81155123190
-
RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
-
Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, ONeill V, Rugo HS (2011) RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29(32): 4286-4293.
-
(2011)
J Clin Oncol
, vol.29
, Issue.32
, pp. 4286-4293
-
-
Brufsky, A.M.1
Hurvitz, S.2
Perez, E.3
Swamy, R.4
Valero, V.5
ONeill, V.6
Rugo, H.S.7
-
4
-
-
84883050174
-
Adjuvant bevacizumabcontaining therapy in triple-negative breast cancer (BEATRICE): Primary results of a randomised, phase 3 trial
-
Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, Bubuteishvili-Pacaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R (2013) Adjuvant bevacizumabcontaining therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 14(10): 933-942.
-
(2013)
Lancet Oncol
, vol.14
, Issue.10
, pp. 933-942
-
-
Cameron, D.1
Brown, J.2
Dent, R.3
Jackisch, C.4
Mackey, J.5
Pivot, X.6
Steger, G.G.7
Suter, T.M.8
Toi, M.9
Parmar, M.10
Laeufle, R.11
Im, Y.H.12
Romieu, G.13
Harvey, V.14
Lipatov, O.15
Pienkowski, T.16
Cottu, P.17
Chan, A.18
Im, S.A.19
Hall, P.S.20
Bubuteishvili-Pacaud, L.21
Henschel, V.22
Deurloo, R.J.23
Pallaud, C.24
Bell, R.25
more..
-
5
-
-
84866002291
-
The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data
-
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2(5): 401-404.
-
(2012)
Cancer Discov
, vol.2
, Issue.5
, pp. 401-404
-
-
Cerami, E.1
Gao, J.2
Dogrusoz, U.3
Gross, B.E.4
Sumer, S.O.5
Aksoy, B.A.6
Jacobsen, A.7
Byrne, C.J.8
Heuer, M.L.9
Larsson, E.10
Antipin, Y.11
Reva, B.12
Goldberg, A.P.13
Sander, C.14
Schultz, N.15
-
7
-
-
0023543690
-
On the presence of chromaffin cells in the adrenal cortex: Their possible role in adrenocortical function
-
Gallo-Payet N, Pothier P, Isler H (1987) On the presence of chromaffin cells in the adrenal cortex: their possible role in adrenocortical function. Biochem Cell Biol 65(6): 588-592.
-
(1987)
Biochem Cell Biol
, vol.65
, Issue.6
, pp. 588-592
-
-
Gallo-Payet, N.1
Pothier, P.2
Isler, H.3
-
8
-
-
84875740314
-
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal
-
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6(269): pl1.
-
(2013)
Sci Signal
, vol.6
, Issue.269
, pp. pl1
-
-
Gao, J.1
Aksoy, B.A.2
Dogrusoz, U.3
Dresdner, G.4
Gross, B.5
Sumer, S.O.6
Sun, Y.7
Jacobsen, A.8
Sinha, R.9
Larsson, E.10
Cerami, E.11
Sander, C.12
Schultz, N.13
-
9
-
-
84888138764
-
A genetic basis for the variable effect of smoking/nicotine on Parkinsons disease
-
Hill-Burns EM, Singh N, Ganguly P, Hamza TH, Montimurro J, Kay DM, Yearout D, Sheehan P, Frodey K, McLear JA, Feany MB, Hanes SD, Wolfgang WJ, Zabetian CP, Factor SA, Payami H (2013) A genetic basis for the variable effect of smoking/nicotine on Parkinsons disease. Pharmacogenomics J 13(6): 530-537.
-
(2013)
Pharmacogenomics J
, vol.13
, Issue.6
, pp. 530-537
-
-
Hill-Burns, E.M.1
Singh, N.2
Ganguly, P.3
Hamza, T.H.4
Montimurro, J.5
Kay, D.M.6
Yearout, D.7
Sheehan, P.8
Frodey, K.9
McLear, J.A.10
Feany, M.B.11
Hanes, S.D.12
Wolfgang, W.J.13
Zabetian, C.P.14
Factor, S.A.15
Payami, H.16
-
10
-
-
78049399444
-
Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV)
-
Hurwitz H, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, Chen D, Rosen O (2010) Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). J Clin Oncol 28(suppl): 3039.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3039
-
-
Hurwitz, H.1
Douglas, P.S.2
Middleton, J.P.3
Sledge, G.W.4
Johnson, D.H.5
Reardon, D.A.6
Chen, D.7
Rosen, O.8
-
11
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23): 2335-2342.
-
(2004)
N Engl J Med
, vol.350
, Issue.23
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
Berlin, J.7
Baron, A.8
Griffing, S.9
Holmgren, E.10
Ferrara, N.11
Fyfe, G.12
Rogers, B.13
Ross, R.14
Kabbinavar, F.15
-
12
-
-
77955240423
-
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib
-
Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, Venzon D, Liewehr D, English BC, Baum CE, Yarchoan R, Giaccone G, Venitz J, Price DK, Figg WD (2010) Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 29: 95.
-
(2010)
J Exp Clin Cancer Res
, vol.29
, pp. 95
-
-
Jain, L.1
Sissung, T.M.2
Danesi, R.3
Kohn, E.C.4
Dahut, W.L.5
Kummar, S.6
Venzon, D.7
Liewehr, D.8
English, B.C.9
Baum, C.E.10
Yarchoan, R.11
Giaccone, G.12
Venitz, J.13
Price, D.K.14
Figg, W.D.15
-
13
-
-
0033398955
-
SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release
-
Janz R, Goda Y, Geppert M, Missler M, Sudhof TC (1999) SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release. Neuron 24(4): 1003-1016.
-
(1999)
Neuron
, vol.24
, Issue.4
, pp. 1003-1016
-
-
Janz, R.1
Goda, Y.2
Geppert, M.3
Missler, M.4
Sudhof, T.C.5
-
14
-
-
0344761960
-
SV2C is a synaptic vesicle protein with an unusually restricted localization: Anatomy of a synaptic vesicle protein family
-
Janz R, Sudhof TC (1999) SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family. Neuroscience 94(4): 1279-1290.
-
(1999)
Neuroscience
, vol.94
, Issue.4
, pp. 1279-1290
-
-
Janz, R.1
Sudhof, T.C.2
-
15
-
-
84863338437
-
Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib
-
Kim JJ, Vaziri SA, Rini BI, Elson P, Garcia JA, Wirka R, Dreicer R, Ganapathi MK, Ganapathi R (2012) Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 118(7): 1946-1954.
-
(2012)
Cancer
, vol.118
, Issue.7
, pp. 1946-1954
-
-
Kim, J.J.1
Vaziri, S.A.2
Rini, B.I.3
Elson, P.4
Garcia, J.A.5
Wirka, R.6
Dreicer, R.7
Ganapathi, M.K.8
Ganapathi, R.9
-
16
-
-
77954700380
-
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
-
Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28(20): 3239-3247.
-
(2010)
J Clin Oncol
, vol.28
, Issue.20
, pp. 3239-3247
-
-
Miles, D.W.1
Chan, A.2
Dirix, L.Y.3
Cortes, J.4
Pivot, X.5
Tomczak, P.6
Delozier, T.7
Sohn, J.H.8
Provencher, L.9
Puglisi, F.10
Harbeck, N.11
Steger, G.G.12
Schneeweiss, A.13
Wardley, A.M.14
Chlistalla, A.15
Romieu, G.16
-
17
-
-
37549040613
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
-
Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26): 2666-2676.
-
(2007)
N Engl J Med
, vol.357
, Issue.26
, pp. 2666-2676
-
-
Miller, K.1
Wang, M.2
Gralow, J.3
Dickler, M.4
Cobleigh, M.5
Perez, E.A.6
Shenkier, T.7
Cella, D.8
Davidson, N.E.9
-
18
-
-
1442265950
-
Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes
-
Danish Breast Cancer Co-operative Group
-
Olsen KE, Knudsen H, Rasmussen BB, Balslev E, Knoop A, Ejlertsen B, Nielsen KV, Schonau A, Overgaard J. Danish Breast Cancer Co-operative Group (2004) Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol 43(1): 35-42.
-
(2004)
Acta Oncol
, vol.43
, Issue.1
, pp. 35-42
-
-
Olsen, K.E.1
Knudsen, H.2
Rasmussen, B.B.3
Balslev, E.4
Knoop, A.5
Ejlertsen, B.6
Nielsen, K.V.7
Schonau, A.8
Overgaard, J.9
-
19
-
-
33746512512
-
Principal components analysis corrects for stratification in genome-wide association studies
-
Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38(8): 904-909.
-
(2006)
Nat Genet
, vol.38
, Issue.8
, pp. 904-909
-
-
Price, A.L.1
Patterson, N.J.2
Plenge, R.M.3
Weinblatt, M.E.4
Shadick, N.A.5
Reich, D.6
-
20
-
-
84881257528
-
Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE study
-
Ramsey TL, Liu Q, Massey BW, Brennan MD (2013) Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE study. Schizophr Res 149(1-3): 21-25.
-
(2013)
Schizophr Res
, vol.149
, Issue.1-3
, pp. 21-25
-
-
Ramsey, T.L.1
Liu, Q.2
Massey, B.W.3
Brennan, M.D.4
-
21
-
-
79955767772
-
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib
-
Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS, Motzer RJ (2011) Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103(9): 763-773.
-
(2011)
J Natl Cancer Inst
, vol.103
, Issue.9
, pp. 763-773
-
-
Rini, B.I.1
Cohen, D.P.2
Lu, D.R.3
Chen, I.4
Hariharan, S.5
Gore, M.E.6
Figlin, R.A.7
Baum, M.S.8
Motzer, R.J.9
-
22
-
-
79953874259
-
RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer
-
Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, OShaughnessy J (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29(10): 1252-1260.
-
(2011)
J Clin Oncol
, vol.29
, Issue.10
, pp. 1252-1260
-
-
Robert, N.J.1
Dieras, V.2
Glaspy, J.3
Brufsky, A.M.4
Bondarenko, I.5
Lipatov, O.N.6
Perez, E.A.7
Yardley, D.A.8
Chan, S.Y.9
Zhou, X.10
Phan, S.C.11
Oshaughnessy, J.12
-
23
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. [Erratum appears in N Engl J Med. 2007;356(3)318]
-
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. [Erratum appears in N Engl J Med. 2007;356(3):318] N Engl J Med 355(24): 2542-2550.
-
(2006)
N Engl J Med
, vol.355
, Issue.24
, pp. 2542-2550
-
-
Sandler, A.1
Gray, R.2
Perry, M.C.3
Brahmer, J.4
Schiller, J.H.5
Dowlati, A.6
Lilenbaum, R.7
Johnson, D.H.8
-
24
-
-
84866849940
-
Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment
-
Schneider BP, Shen F, Miller KD (2012) Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment. Lancet Oncol 13(10): e427-e436.
-
(2012)
Lancet Oncol
, vol.13
, Issue.10
, pp. e427-e436
-
-
Schneider, B.P.1
Shen, F.2
Miller, K.D.3
-
25
-
-
79959304867
-
Anti-vascular endothelial growth factor therapy for breast cancer: Can we pick the winners?
-
Schneider BP, Sledge Jr GW (2011) Anti-vascular endothelial growth factor therapy for breast cancer: can we pick the winners? J Clin Oncol 29(18): 2444-2447.
-
(2011)
J Clin Oncol
, vol.29
, Issue.18
, pp. 2444-2447
-
-
Schneider, B.P.1
Sledge, G.W.2
-
26
-
-
53749093040
-
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
-
Ecog 2100
-
Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD. Ecog 2100 (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26(28): 4672-4678.
-
(2008)
J Clin Oncol
, vol.26
, Issue.28
, pp. 4672-4678
-
-
Schneider, B.P.1
Wang, M.2
Radovich, M.3
Sledge, G.W.4
Badve, S.5
Thor, A.6
Flockhart, D.A.7
Hancock, B.8
Davidson, N.9
Gralow, J.10
Dickler, M.11
Perez, E.A.12
Cobleigh, M.13
Shenkier, T.14
Edgerton, S.15
Miller, K.D.16
-
27
-
-
84899906863
-
In Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumabbevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer
-
10-14 December 2013; San Antonio, TX, USA, abstract S1-03
-
Slamon DJ, Swain SM, Buyse M, Martin M, Geyer CE, Im Y-H, Pienkowski T, Kim S-B, Robert NJ, Steger G, Crown J, Verma S, Eiermann W, Costantino JP, Im S-A, Mamounas EP, Schwartzberg L, Paterson A, Mackey JR, Provencher L, Press MF, Thirlwell M, Bee- Munteanu V, Henschel V, Crepelle-Flechais A, Wolmark N (2013) In Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumabbevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer. San Antonio Breast Cancer Symposium. 10-14 December 2013; San Antonio, TX, USA, abstract S1-03.
-
(2013)
San Antonio Breast Cancer Symposium
-
-
Slamon, D.J.1
Swain, S.M.2
Buyse, M.3
Martin, M.4
Geyer, C.E.5
Im, Y.-H.6
Pienkowski, T.7
Kim, S.-B.8
Robert, N.J.9
Steger, G.10
Crown, J.11
Verma, S.12
Eiermann, W.13
Costantino, J.P.14
Im, S.-A.15
Mamounas, E.P.16
Schwartzberg, L.17
Paterson, A.18
Mackey, J.R.19
Provencher, L.20
Press, M.F.21
Thirlwell, M.22
Bee- Munteanu, V.23
Henschel, V.24
Crepelle-Flechais, A.25
Wolmark, N.26
more..
-
28
-
-
84879176226
-
A genome-wide association study for venous thromboembolism: The extended cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium
-
Tang W, Teichert M, Chasman DI, Heit JA, Morange PE, Li G, Pankratz N, Leebeek FW, Pare G, de Andrade M, Tzourio C, Psaty BM, Basu S, Ruiter R, Rose L, Armasu SM, Lumley T, Heckbert SR, Uitterlinden AG, Lathrop M, Rice KM, Cushman M, Hofman A, Lambert JC, Glazer NL, Pankow JS, Witteman JC, Amouyel P, Bis JC, Bovill EG, Kong X, Tracy RP, Boerwinkle E, Rotter JI, Tregouet DA, Loth DW, Stricker BH, Ridker PM, Folsom AR, Smith NL (2013) A genome-wide association study for venous thromboembolism: the extended cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. Genet Epidemiol 37(5): 512-521.
-
(2013)
Genet Epidemiol
, vol.37
, Issue.5
, pp. 512-521
-
-
Tang, W.1
Teichert, M.2
Chasman, D.I.3
Heit, J.A.4
Morange, P.E.5
Li, G.6
Pankratz, N.7
Leebeek, F.W.8
Pare, G.9
De Andrade, M.10
Tzourio, C.11
Psaty, B.M.12
Basu, S.13
Ruiter, R.14
Rose, L.15
Armasu, S.M.16
Lumley, T.17
Heckbert, S.R.18
Uitterlinden, A.G.19
Lathrop, M.20
Rice, K.M.21
Cushman, M.22
Hofman, A.23
Lambert, J.C.24
Glazer, N.L.25
Pankow, J.S.26
Witteman, J.C.27
Amouyel, P.28
Bis, J.C.29
Bovill, E.G.30
Kong, X.31
Tracy, R.P.32
Boerwinkle, E.33
Rotter, J.I.34
Tregouet, D.A.35
Loth, D.W.36
Stricker, B.H.37
Ridker, P.M.38
Folsom, A.R.39
Smith, N.L.40
more..
-
29
-
-
84884401355
-
Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: A phase III randomized trial of the Gynecologic Oncology Group
-
abstract 3
-
Tewari KS, Sill M, Long HJ, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ (2013) Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. J Clin Oncol 31(Suppl): abstract 3.
-
(2013)
J Clin Oncol
, vol.31
-
-
Tewari, K.S.1
Sill, M.2
Long, H.J.3
Ramondetta, L.M.4
Landrum, L.M.5
Oaknin, A.6
Reid, T.J.7
Leitao, M.M.8
Michael, H.E.9
Monk, B.J.10
-
30
-
-
84938374997
-
Randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study
-
abstract 2001
-
Walter Taal Oosterkamp HM, Walenkamp AME, Beerepoot LV, Hanse M, Buter J, Honkoop Boerman f, Dol A (2013) randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study. J Clin Oncol 31(Suppl): abstract 2001.
-
(2013)
J Clin Oncol
, vol.31
-
-
Walter Taal Oosterkamp, H.M.1
Walenkamp, A.M.E.2
Beerepoot, L.V.3
Hanse, M.4
Buter, J.5
Honkoop Boermanf Dol, A.6
-
31
-
-
0034908225
-
SV2 modulates the size of the readily releasable pool of secretory vesicles
-
Xu T, Bajjalieh SM (2001) SV2 modulates the size of the readily releasable pool of secretory vesicles. Nat Cell Biol 3(8): 691-698.
-
(2001)
Nat Cell Biol
, vol.3
, Issue.8
, pp. 691-698
-
-
Xu, T.1
Bajjalieh, S.M.2
-
32
-
-
0042343801
-
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
-
Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5): 427-434.
-
(2003)
N Engl J Med
, vol.349
, Issue.5
, pp. 427-434
-
-
Yang, J.C.1
Haworth, L.2
Sherry, R.M.3
Hwu, P.4
Schwartzentruber, D.J.5
Topalian, S.L.6
Steinberg, S.M.7
Chen, H.X.8
Rosenberg, S.A.9
|